Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 6Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1

Interventions

Cyclophosphamide 10Etoposide 6Doxorubicin 6Cytarabine 6Prednisone 5Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4Methotrexate 4gamma-Globulins 3Rituximab 3Radiotherapy 3Filgrastim 3Ciprofloxacin 3pegaspargase 2nelarabine 2etoposide phosphate 2calaspargase pegol 2Triptorelin Pamoate 2Thioguanine 2Prednisolone 2Methylprednisolone 2Mercaptopurine 2Melphalan 2Magnetic Resonance Spectroscopy 2Immunoglobulins, Intravenous 2Dexamethasone 2Daunorubicin 2Cyclosporine 2Calcium Dobesilate 2Bortezomib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lymphoma × Hydrocortisone × Clear all
NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡